All News
Can be challenging to identify early/impending MAS in AoSD. Ruscitti et al propose a model based on systemic score, ferritin, IFN-γ, and IL-10 with AUC 0.99, sensitivity 100% specificity 95% @RheumNow #EULAR2022 OP0044 https://t.co/bbWkdGCnHP
Links:
Richard Conway RichardPAConway ( View Tweet)
More from the VITAL study Dr Costenbader @karen_kc123 et al. 5 year supplementation followed 2 year follow up. Vit D 2000iu ⬇️incident autoimmune disease 21%. RA, PMR, psoriasis trend towards reduction. No effect omega-3 @RheumNow #EULAR2022 OP0038 https://t.co/kbKqDhtN9z https://t.co/HcFXbweEPm
Links:
Richard Conway RichardPAConway ( View Tweet)
Severe heme relapses are common in #SLE pts w/prior severe heme episodes: ATTIKON SLE cohort 800 pts
👉13% w/severe heme dz: TMA, MAS, plt < 30K, hemolysis hgb < 8
👉heme issues preceded SLE dx in 1/3 of pts
👉>50% pts had severe heme flare
👉0 deaths #EULAR2022 @rheumnow POS0116
TheDaoIndex KDAO2011 ( View Tweet)
Low rates of hypersensitivity reactions (HSR) to #anifrolumab
Pooled data MUSE & TULIP-1/-2 w/1100 pts:
👉1 anaphylaxis (0.15%)
👉12 HSR (3%)
👉43 infusion reaction (9%): N/V/headache
👉most easily treatable w/antihistamine, GCs, acetaminophen
#EULAR2022 POS0708 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
Another study that shows longterm exposure to pollutants can increased risk for autoimmune/immune mediated inflammatory diseases #EULAR2022 OP0071 @rheumnow #SaveEarth https://t.co/hMFJfEOcV1
TheDaoIndex KDAO2011 ( View Tweet)
Once we add adalimumab in MTX-IR RA, can we dial down MTX & still keep control?
New data - now in East Asian pts (with already low MTX) says often yes, without ⬆️ADAb.
Obviously RA control 1st/2nd/3rd, but prob doesn’t have to be MTX 20 forever in everyone #EULAR2022 @RheumNow https://t.co/aZ0bsgY7dC
David Liew drdavidliew ( View Tweet)
It's not a museum. It's the new, look, all electronic poster sessions. Rows & rows of 42 inch touch screen monitors on the wall. You can interact with these online monitors, but I was unable to connect to Netflix. #EULAR22 https://t.co/yYb0HaMWHJ
Dr. John Cush RheumNow ( View Tweet)
Prof Pickering explained interpretation of Low Complement level and its association with Complement Pathways and Diseases #EULAR2022 @RheumNow
💠 ⬇️C4, normal/⬇️C3: Classical
💠 ⬇️C3, normal C4: Alternative https://t.co/fBKKNzWnNW
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
We are back!!! #EULAR22 https://t.co/njNKyVqu5u
Dr. John Cush RheumNow ( View Tweet)
in case you're interesting in the causal diagram for the mediation modelling for this:
far from proven, but certainly does raise some questions about a potential advantage of IL-23 inhibitors in a crowded PsA market #EULAR2022 @RheumNow https://t.co/bSuE3tDHUO
David Liew drdavidliew ( View Tweet)
Top Influencers of #EULAR2022: @eular_org @EMEUNET @RheumNow @ARD_BMJ @RichardPAConway @Yuz6Yusof @ProftDr More 📊 https://t.co/fUfohEZAoX
Symplur Hashtags healthhashtags ( View Tweet)
Interesting, NWA by Dougados et al shows both Tofa and ADA may benefit pain in those who have controlled inflammatory component. ?real effect vs imperfect measures @RheumNow #EULAR2022 OP0052 https://t.co/aYBTaSDa3v https://t.co/dkLv1l5tFy
Links:
Richard Conway RichardPAConway ( View Tweet)
#POS0065 #EULAR2022 What is the nature of ILD progression in #Sjogren and is it mostly stable? A cohort study in Oslo (N=702) showed after 15 yrs follow-up, 45% had radiographic progression. Hence, need to monitor lung function test @RheumNow https://t.co/ga7qer27ks
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#POS0263 #EULAR2022 In #rituximab-treated RMD patients with undetectable humoral response to primary #COVID 💉, a study (N=84) found Re-Vaccination with mRNA (2 shots) was better than a Booster (1 shot). Lend support for current approach: 2 + 3rd Primary + Booster @RheumNow https://t.co/AH0wpVKbHc
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Burja et al. Dimethyl alpha-ketoglutarate has anti-inflammatory and anti-fibrotic effects on explanted systemic sclerosis skin. @RheumNow #EULAR2022 OP0095 https://t.co/PSbnVh6uta https://t.co/2ij9HgoU6Q
Links:
Richard Conway RichardPAConway ( View Tweet)
RheumNow Coverage of #EULAR2022 Presents Live Expert Discussions https://t.co/FeE0WfXw1z
Dr. John Cush RheumNow ( View Tweet)
Phase 3 RCT upadacitinib in nrAxSpA. Clinical (ASAS40), PRO, and radiologic response seen at week 14 vs placebo @RheumNow #EULAR2022 OP0016 https://t.co/s3Vf4QiiAD https://t.co/gzlxZ3sxHF
Links:
Richard Conway RichardPAConway ( View Tweet)
#EULAR2022 OP0073: Gender-specific assessment for MRI imaging criteria
⭐️Sex differences in axSpA - disease presentations, jt biomechanics, diagnostic delay in ♀️
⭐️Higher fat metaplasia in ♂️, Sclerosis in ♀️
⭐️Ankylosis much higher in ♂️ (DOR 40!)
@Rheumnow
Eric Dein ericdeinmd ( View Tweet)
#What’sHot? Axial PsA cohort as some drugs seem to work differently in axPsA vs axSpA Less HLAB27+, less male, 17% isolated axial in PsA #OP0026 @RheumNow #EULAR2022 @eular_org https://t.co/I0azSymVrr
Janet Pope Janetbirdope ( View Tweet)
Intra-articular morphine in knee arthritis. WHAT!? Not-surprisingly it doesn't work. Inferior to steroid and same as placebo. Still kudos to Haibel et al for answering this question @RheumNow #EULAR2022 OP0050 https://t.co/zjY36V9OCS https://t.co/j67omCQCxI
Links:
Richard Conway RichardPAConway ( View Tweet)